GoodRx Holdings (GDRX) Other financing activities (2019 - 2026)

GoodRx Holdings has disclosed Other financing activities across 8 years of filings, most recently posting $274000.0 for Q2 2026.

• In Q2 2026, Other financing activities fell 68.07% year-over-year to $274000.0; the TTM figure through Jun 2026 stood at $817000.0 (down 89.96% YoY), while the FY2025 annual figure was $1.3 million, down 93.13% from the prior year.
• Other financing activities came in at $274000.0 for Q2 2026 at GoodRx Holdings, up from $95000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $9.2 million in Q2 2024 to a low of $2000.0 in Q1 2025.
• Average Other financing activities over 5 years is $2.1 million, with a median of $858000.0 recorded in 2025.
• Year-over-year, Other financing activities plunged 99.92% in 2025 and jumped 4650.0% in 2026.
• Over 5 years, Other financing activities stood at $49000.0 in 2022, then surged by 3075.51% to $1.6 million in 2023, then plunged by 60.73% to $611000.0 in 2024, then fell by 26.68% to $448000.0 in 2025, then slumped by 38.84% to $274000.0 in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $274000.0 in Q2 2026, $95000.0 in Q1 2026, and $448000.0 in Q4 2025.